Photo from Lucence/LinkedIn
Jul 8, 2024, 04:44
A comprehensive NGS test supporting decisions in blood cancers – Lucence
Lucence shared a post on LinkedIn:
“Swift Sensitive Surveillance. Because Cure Matters.
Proud to announce our new HemeMark service upgrade – now immediately available. HemeMark is a comprehensive NGS test supporting decisions in blood cancers.
Key features:
- 72 genes (from 45 genes) and microsatellite instability (MSI) more useful actionable information guiding treatment decisions.
- 0.05% VAF (from 0.1% VAF) for even greater sensitivity, powered by our proprietary mirror barcodes.
- 2 weeks turnaround time
- Run in our CAP-accredited and CLIA-licensed laboratory.
100% concordance of mutations in paired blood and bone marrow has been shown at >0.5% VAF threshold using HemeMark, and 86% at >0.1% threshold (Lim B et al, AACR 2023)
For non-US physicians only.”
Min-Han Tan, Founding CEO of Lucence, shared this post, adding:
“Glad for this upgrade of HemeMark to support physicians caring for patients with leukemias and lymphomas.”
Sources: Lucence/LinkedIn and Min-Han Tan/LinkedIn .
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19